Kinito (Itopride Hydrochloride)

Itopride blocks dopamine D2 receptors in the gastrointestinal tract and inhibits acetylcholinesterase, increasing acetylcholine activity. This dual action stimulates coordinated smooth‑muscle contractions, enhancing gastric motility and promoting more efficient emptying of stomach contents.

The dose of Kinito is determined by the prescribing healthcare professional based on the patient’s condition, age, and response. Physicians select the appropriate strength and dosing schedule according to current clinical guidelines and product labeling.

Safety data for Itopride Hydrochloride in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Kinito. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kinito’s active ingredient, Itopride, combines dopamine‑D2 antagonism with acetylcholinesterase inhibition, offering a dual mechanism that may provide faster gastric emptying compared with agents that act solely on one pathway, such as metoclopramide or domperidone. However, therapeutic choice depends on individual patient factors and physician judgment.

Kinito should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture, light and excessive heat. Keeping the product in a dry, well‑ventilated area helps maintain its stability throughout its shelf life.

Kinito is taken orally, usually with a glass of water. The tablet (or other oral form) may be taken before meals or as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Although uncommon, serious adverse reactions can include severe skin rash, hepatic dysfunction, blood dyscrasias such as neutropenia, and anaphylactic‑type hypersensitivity. Any signs of these conditions require immediate medical attention and discontinuation of the drug.

Kinito is contraindicated in individuals with known hypersensitivity to Itopride Hydrochloride or any excipients, and should be avoided in patients with severe renal or hepatic impairment unless specifically advised by a physician. Caution is also advised for the elderly and for those taking interacting medications.